

GLOBAL VALUE DOSSIER
FOR MINIMALLY INVASIVE SURGERY (MIS)
THORACIC SURGERY

Medtronic
Further, Together

Prepared by:

Jayne Smith-Palmer

Ossian Health Economics and Communications, Bäumleingasse 20, 4051
Basel, Switzerland

Phone: +41 61 271 6214

E-mail: smith-palmer@ossianconsulting.com

Version No.

2

Date:

March 18, 2016

Contents

1. Video-assisted thoracic surgery (wedge, segmentectomy, lobectomy).....	4
1.1. Overview of procedure.....	4
1.2. Clinical and economic outcomes with VATS versus open thoracic surgery for pulmonary resection.....	10
1.1.1. Clinical and economic evidence tables	18
1.3. References	33

List of Tables

Table 1-1 Summary of meta-analyses comparing video-assisted versus open thoracic surgery.....	19
Table 1-2 Summary of key clinical studies comparing video-assisted versus open thoracic surgery.....	21
Table 1-3 Summary of key studies comparing economic outcomes of video assisted versus open thoracic surgery	29

List of Figures

Figure 1-1 Indications for VATS major pulmonary resection in Russia	5
Figure 1-2 Wedge resection (segmentectomy), lobectomy and pneumonectomy	6
Figure 1-3 Sleeve lobectomy.....	7
Figure 1-4 Length of stay with VATS lobectomy versus open lobectomy.....	12
Figure 1-5 Estimated blood loss with VATS versus open lobectomy.....	13
Figure 1-6 Mean (or median) operating time for VATS versus open lobectomy.....	14
Figure 1-7 Incidence of SSI with VATS versus open lobectomy.....	15
Figure 1-8 5 year survival rates in lung cancer patients undergoing VATS or open pulmonary resection	16
Figure 1-9 Total hospital costs of VATS versus open pulmonary resection in studies conducted in Europe	17
Figure 1-10 Total hospital costs of VATS versus open pulmonary resection in US-based studies	18

1. Video-assisted thoracic surgery (wedge, segmentectomy, lobectomy)


1.1. Overview of procedure

Video-assisted thoracic surgery (VATS) is used for both diagnostic and therapeutic procedures, with VATS procedures including wedge resections, segmentectomy, lobectomy, sleeve resections and pneumonectomy. VATS is becoming increasingly used for stage I and II non-small cell lung cancer (NSCLC) as well as in the treatment of spontaneous pneumothorax, biopsy and several benign conditions. The increased use of VATS in recent years has been partly attributed to improvements in optics and instrumentation and better anesthesia.¹ VATS is preferred to open surgery, especially for some populations including those with pulmonary compromise, advanced age or impaired wound healing. Relative contraindications to VATS include tumor >6 cm in diameter. A key benefit of VATS over open surgery is reduced post-operative pain and reduced trauma to the chest wall as VATS, or thoracoscopic surgery, utilizes small incisions rather than the long incision required in traditional thoracotomy.

One of the most common indications for VATS procedures is NSCLC, which is one of the most commonly occurring cancers in the US and Europe, with >220,000 new cases of lung cancer in the US in 2015² and >380,000 cases in Europe in 2008.³ The use of VATS procedures in the US is continuing to increase at approximately 5% per year from an estimated 26,000 per year in 2005 to 43,000 per year in 2014.¹ Additionally, the economic burden associated with lung resections is substantial; in the US alone, the cost of lung resections is an estimated USD 1.9 billion per year.⁴

Typically, VATS procedures are performed with the patient in the lateral decubitus position with flexion of the operating table (to widen the intercostal spaces) and require general anesthesia with isolation of one lung and utilize three incisions including one utility incision (ranging from 4–10 cm in length, providing instrument access and through which the resected material is removed) and two for instrument access; however, some procedures can be performed using a single port. Lung cancer is the most common indication for major pulmonary resections with VATS (Figure 1-1); where the indication for VATS is lung cancer, hilar and mediastinal lymphadenectomy or node sampling are performed.

Figure 1-1 Indications for VATS major pulmonary resection in Russia




Source: Pischik 2014⁵

Wedge resection/segmentectomy

Indications for wedge resection include stage I NSCLC or solitary metastases (<3cm) in patients who would not tolerate a lobectomy (e.g. those with pulmonary hypertension or severe comorbid conditions) as well as indeterminate pulmonary nodules and benign disease (Figure 1-2).^{1,6} VATS wedge resection involves three incisions with the camera port typically located at the seventh or eighth intercostal space. The most common resection technique is resection with mechanical endoscopic staplers. The removed tissue is extracted using a specimen sac. The final stages for both lobectomy and wedge resection is pleural lavage followed by the insertion of one or two chest drains into the pleural cavity via the port incisions; these are removed only when air leakage stops and fluid drainage is minimal.

Figure 1-2 Wedge resection (segmentectomy), lobectomy and pneumonectomy



Source: Colorado Cardiovascular Surgical Associates (available at: <http://ccvsa.com/medical-surgical-procedures/thoracic-surgery>)

Lobectomy

VATS lobectomy involves the removal of an entire lobe of the lung and is a relatively commonly performed procedure (Figure 1-2). Indications for lobectomy include stage I or II NSCLC in patients with sufficient pulmonary reserve to tolerate lobectomy as well as benign conditions such as granuloma, organized pneumonia, bronchiectasis, abscess and malformations.⁶ VATS lobectomy typically utilizes three incisions; the hilar structures are dissected first, after which the pulmonary vessels and bronchi within the hilum are then dissected, most commonly using endoscopic staplers.

Pneumonectomy

Pneumonectomy is a rarely performed procedure and a relatively low proportion of pneumonectomy procedures are performed using VATS and involves the removal of the entire lung, making it the most extensive pulmonary resection, pneumonectomy is generally avoided if other procedures can be performed instead of pneumonectomy (Figure 1-2). One of the most common indications for VATS pneumonectomy is bronchial tumors that cannot be resected using sleeve lobectomy. Three incisions are typically used and soft tissues retracted at the access incision, this is followed by hilar dissection then dissection of the pulmonary vessels, the lung is then then extracted from the thoracic cavity through the utility port using a specimen sac.⁷

Sleeve lobectomy


Sleeve lobectomy using VATS was first reported in 2002 but is not common and generally only performed by thoracic surgeons with considerable experience in VATS. Sleeve lobectomy is the most common bronchoplastic resection procedure, and involves circumferential airway resection and end-to-end anastomosis to join the remaining airways (Figure 1-3).⁸ The most common indications for sleeve lobectomy are benign or low grade malignant neoplasms or stenoses involving the main or lobar bronchi. Sleeve lobectomy is also indicated for patients who have compromised cardiopulmonary function ($FEV_1 < 50\%$

predicted¹ and maximum voluntary ventilation <50% predicted value) to preserve lung parenchyma and avoid pneumonectomy.

Sleeve lobectomy may be performed for any lobe but the most common site for sleeve lobectomy is right upper lobe followed by the left upper lobe; left lobe sleeve resections are more technically challenging owing to the proximity of the aorta and left recurrent nerve.

The procedure begins with dividing hilar structures followed by identification and transection of the pulmonary vessels then bronchial resection and anastomosis. Possible complications following sleeve lobectomy include sputum retention, bronchovascular and bronchopulmonary fistula, and anastomotic failure.

Figure 1-3 Sleeve lobectomy



Source: Gonzalez-Rivas et al. 2014⁹

¹ FEV1; forced expiratory volume in 1 second

Guidelines on VATS

2007 Recommendations from the Consensus Statement of the International Society of Minimally Invasive Cardiothoracic Surgery¹⁰

For patients with clinical stage I non-small cell lung cancer (NSCLC) undergoing lung lobectomy

- VATS can be recommended to reduce overall postoperative complications (class IIa, level A evidence)
- VATS can be recommended to reduce pain and overall functionality over the short term (class IIa, level B evidence)
- VATS can be recommended to improve delivery of adjuvant chemotherapy delivery (class IIa, level B evidence)
- VATS can be recommended for lobectomy in clinical stage I and II NSCLC patients with no proven difference in stage-specific 5-year survival compared with open thoracotomy (class IIb, level B evidence)

2014 Recommendations from the Japanese Association for Chest Surgery

For patients with pneumothorax undergoing surgery¹¹

- VATS is broadly indicated as surgery for pneumothorax
- VATS is judged to be less invasive, as it results in minimal post-operative pain, the periods of chest tube placement and hospitalization are short, and it shows a trend toward early realization of social integration
- There is no difference in terms of safety and complications between VATS and open thoracotomy
- As it is anticipated that VATS will result in a higher recurrence rate than open thoracotomy, it may be desirable to add a supplemental procedure during surgery

For patients with lung cancer¹²

- VATS lobectomy may be considered and applied for patients with clinical stage I NSCLC; however, well-established evidence is lacking (Recommendation grade: Level C1)
VATS lobectomy by an experienced thoracic surgeon may be considered for patients with clinical stage I NSCLC
- VATS lobectomy is estimated to be less invasive
- VATS showed better or at least equivalent outcomes regarding intra- or postoperative complications compared with thoracotomy
- Long-term survival by VATS lobectomy is suggested to be at least equivalent, although there is lack of evidence

2013 Recommendations from the American College of Chest Physicians (ACCP) for the treatment of patients with stage I and II NSCLC¹³

Lobectomy: for patients with clinical stage I NSCLC, a minimally invasive approach such as VATS (thoracoscopy) is preferred over a thoracotomy for anatomic pulmonary resection and is suggested in experienced centers (Grade 2C)

1.2. Clinical and economic outcomes with VATS versus open thoracic surgery for pulmonary resection

Key findings

Clinical outcomes

- **Length of stay:** Studies show that in patients undergoing lobectomy VATS was consistently associated with a shorter LoS than open surgery (Figure 1-4), with this difference achieving statistical significance in several individual studies^{28,30,33,34,36,38,41,44,46}, and meta-analyses.^{23,25}
- **Blood loss:** Mean (or median) blood loss was consistently and significantly lower with VATS lobectomy compared with open lobectomy in individual studies^{38,46,50,51} (Figure 1-5) and meta-analyses^{23,25}
- **Blood transfusion:** A lower proportion of patients undergoing VATS resection required blood transfusion compared with those undergoing open lung resection^{32,38,39,44,46} in the majority of these the difference was significant^{32,38,39,46}
- **Operating time:** VATS lobectomy was associated with significantly longer operating times than open lobectomy across several studies (Figure 1-6).^{44,47} However, some studies showed operating times to be significantly shorter with VATS lobectomy compared with open lobectomy^{38,50,51}
- **Surgical Site Infection:** In general, rates of SSI were similar for lobectomy performed as an open procedure or VATS;^{28,39,46} one study reported a significantly lower incidence of SSI with VATS versus open lobectomy³⁵ (Figure 1-7)
- **Overall survival:** For patients undergoing lung resection for lung cancer, 5 year survival rates were similar for open and VATS resection (Figure 1-8)^{27,40,41} One 2015 study⁴⁹ and two meta-analyses showed a significant survival benefit in favor of VATS^{23,24}
- **Chest tubes:** Meta-analyses showed that the length of time chest tube drainage was required was significantly shorter with VATS than open lobectomy^{23,25}; findings among individual studies were inconsistent, two reported a significant difference in favor of VATS^{38,39} but four reported no significance difference^{47,49,50,,51}
- **Post-operative pain:** Post-operative pain scores were lower with VATS versus open lung resection⁴² and the proportion of patients requiring pain medication was also significantly lower⁴⁶

Economic outcomes


- **Total costs:** Overall, in the majority of cost studies included in the analysis, total costs with VATS were lower than for corresponding open procedures, the one exception to this was studies conducted in China where inconsistency was noted
 - **United States:** Total hospital costs in US-based studies were consistently lower with VATS lung resection than with open lung resection (Figure 1-9)^{52,30,37,33,36,48,56} with this difference achieving statistical significance in several studies^{30,37,36,56}

- **Europe:** In studies conducted in Europe (UK and France) total hospital costs were significantly lower with VATS lung resection than with open lung resection (Figure 1-10)⁴⁴
- **China:** Findings of cost studies from China were inconsistent, one study reported lower costs with VATS versus open surgery²³ but a second study reported significantly higher total costs with VATS⁵¹
- **Savings due to clinical benefits:** Studies presenting a breakdown of total costs demonstrate that the lower post-operative ward stay costs, primarily due to a shorter LoS are a key driver of lower overall costs.^{43,44,53} The lower rate of post-operative complications with VATS is also likely to translate into economic benefits

Other findings


- **Learning curve:** Operating time for VATS procedures is influenced by surgeon experience and a learning curve is evidence with operating time decreasing as surgeon experience increases.^{14,15,16} Higher levels of surgeon experience is also associated with reduced costs.¹⁵
- **Barriers to use:** A survey of surgeons showed that 92% of surgeons are willing to learn VATS lobectomy, but barriers included limited resources (50%), limited exposure/mentoring (45%) and limited clinical evidence (20%). When questioned about the advantages open thoracotomy, a high proportion of surgeons believed that VATS was associated with less post-operative pain (81%), shorter LoS (72%) and higher patient satisfaction (80%).¹⁷
- **Economic impact of complications:** Intra-operative and post-operative complications, which are more common with open surgery, are associated with higher overall costs. For example, in a study of VATS procedures intra-operative blood transfusion increased costs by >USD 15,000 similarly post-operative pneumonia and blood transfusion increased costs by more than USD 2,900 and USD 5,800, respectively.¹⁸
- **Re-admission:** Re-admission within following lung cancer resection is associated with a 6-fold increase in 90-day post-operative mortality.¹⁹
- **Tissue trauma:** Studies looking at inflammatory markers (e.g. tumor necrosis factor- α , interleukin-6, interleukin-8, interleukin-10 and C-reactive protein [CRP]) have shown that VATS is associated with lower levels of interleukin-6 and CRP and a quicker return of immune function compared with open lobectomy, although the significance of this remains unknown.²⁰
- **Pulmonary function:** In a Japanese study of n=204 patients (n=42 with dyspnea) undergoing major lung resections (mean age 64 years) post-operative pulmonary function (including FEV₁ and FVC) shows significantly better improvement in patients undergoing VATS compared with those undergoing open thoracotomy²¹
- **High risk patients:** The benefits of VATS relative to open lobectomy in terms of reduced complications may be of particular importance in patients considered to be high risk, such as those with substantial pre-operative comorbidities.²⁰
- **Quality of life:** Compared with open lobectomy VATS lobectomy has been shown to be associated with a better profile in terms of quality of life and faster return to normal activities²²

Figure 1-4 Length of stay with VATS lobectomy versus open lobectomy




*p<0.05; **p<0.01; ***p<0.001; NR, not reported; ns, not significant

Figure 1-5 Estimated blood loss with VATS versus open lobectomy




*p<0.05; **p<0.01; ***p<0.001; NR, not reported; ns, not significant

Figure 1-6 Mean (or median) operating time for VATS versus open lobectomy




*p<0.05; **p<0.01; ***p<0.001; NR, not reported; ns, not significant

Figure 1-7 Incidence of SSI with VATS versus open lobectomy




*p<0.05; **p<0.01; ***p<0.001; NR, not reported; ns, not significant

Figure 1-8 5 year survival rates in lung cancer patients undergoing VATS or open pulmonary resection




*p<0.05; **p<0.01; ***p<0.001; NR, not reported; ns, not significant

Figure 1-9 Total hospital costs of VATS versus open pulmonary resection in studies conducted in Europe



*p<0.05; **p<0.01; ***p<0.001; NR, not reported; ns, not significant

Figure 1-10 Total hospital costs of VATS versus open pulmonary resection in US-based studies



*p<0.05; **p<0.01; ***p<0.001; NR, not reported; ns, not significant

1.1.1. Clinical and economic evidence tables

A summary of clinical evidence on VATS compared with open surgery from published meta-analyses and published studies is shown in Table 1-1 and Table 1-2, respectively. A summary of economic evidence from published cost studies is shown in Table 1-3.

In the following tables outcomes where p<0.05 are underlined.

Table 1-1 Summary of meta-analyses comparing video-assisted versus open thoracic surgery					
Authors	Details	Procedures	Outcome	OR (95% CI)	P value
Chen et al. 2013 ²³	20 studies, n=3,457 patients	VATS versus open lobectomy for stage I non-small cell lung cancer	Peri-operative		
			Operating time, minutes	-14.68 (-4.68, 34.03) ^a	0.14
			<u>Blood loss, mL</u>	<u>-62.49 (-79.32, -45.66)</u>	<u><0.0001</u>
			Post-operative		
			<u>Drainage time, days</u>	<u>-0.39 (-0.69, -0.09)</u>	<u>0.01</u>
			<u>LoS, days</u>	<u>-1.74 (-2.20, -1.20)</u>	<u><0.0001</u>
			<u>Complication incidence</u>	<u>0.61 (0.49, 0.76)</u>	<u><0.0001</u>
Yan et al. 2009 ²⁴	21 studies (2 RCTs and 19 non RCTs), n=2,641 patients	VATS versus open lobectomy for early stage NSCLC	Post-operative		
			Mortality	0.49 (0.06, 3.76)	0.49
			Pneumonia	0.34 (0.10, 1.16)	0.09
			Post-discharge		
			<u>Systemic recurrence</u>	<u>0.57 (0.34, 0.96)</u>	<u>0.03</u>
Cheng et al. 2007 ²⁵	Level A meta-analysis; 3 RCTs, n=205 patients Level B meta-analysis 33 non-RCT studies, n=3,384 patients	VATS versus open (thoracotomy) lobectomy for non-small cell lung cancer	<u>Operating time, minutes</u>	<u>16.17 (2.46, 29.89)^a</u>	<u>0.02</u>
			<u>RCT</u>	<u>7.62 (-24.44, 39.69)^a</u>	<u>0.64</u>
			<u>non-RCT</u>	<u>17.20 (2.62, 31.79)^a</u>	<u>0.02</u>
			<u>Blood loss, mL</u>	<u>-79.1 (-106.9, -52.4)^a</u>	<u><0.0001</u>
			<u>RCT</u>	<u>NA</u>	<u>NA</u>
			<u>non-RCT</u>	<u>-79.1 (-106.9, -52.4)^a</u>	<u><0.0001</u>
			<u>Chest tube drainage, days</u>	<u>-0.96 (-1.59, -0.34)^a</u>	<u>0.002</u>
			<u>RCT</u>	<u>-1.90 (-4.05, 0.25)^a</u>	<u>0.08</u>
			<u>non-RCT</u>	<u>-0.92 (-1.56, -0.28)^a</u>	<u>0.005</u>
			<u>LoS, days</u>	<u>-2.60 (-1.47, -0.72)^a</u>	<u>0.007</u>
			<u>RCT</u>	<u>0.10 (-1.63, 1.83)^a</u>	<u>0.91</u>
			<u>non-RCT</u>	<u>-2.99 (-5.07, -0.91)^a</u>	<u>0.005</u>
			<u>Any complication</u>	<u>0.48 (0.32, 0.70)</u>	<u>0.0002</u>
			<u>RCT</u>	<u>0.30 (0.11, 0.81)</u>	<u>0.02</u>
			<u>non-RCT</u>	<u>0.52 (0.34, 0.80)</u>	<u>0.003</u>
			Pneumonia	0.56 (0.26, 1.21)	0.14
			<u>RCT</u>	<u>0.10 (0.01, 2.17)</u>	<u>0.14</u>
<u>non-RCT</u>	<u>0.68 (0.30, 1.53)</u>	<u>0.35</u>			

Table 1-1 Summary of meta-analyses comparing video-assisted versus open thoracic surgery					
Authors	Details	Procedures	Outcome	OR (95% CI)	P value
			Prolonged air leak (>7 days)	1.67 (0.92, 3.03)	0.09
			RCT	0.38 (0.09, 1.60)	0.19
			<u>non-RCT</u>	<u>2.44 (1.21, 4.90)</u>	<u>0.01</u>
			In-hospital mortality (non-RCT)	0.79 (0.38, 1.64)	0.53

Values below 1.00 favor VATS; values above 1.00 favor open

^aWeighted mean difference, negative values favor VATS

Table 1-2 Summary of key clinical studies comparing video-assisted versus open thoracic surgery							
Study	Setting	Study details	Procedure (year performed)	Summary of clinical findings Endpoint	Open	VATS	P value
Scott et al. 2010²⁶ and Su et al. 2014²⁷	United States	Secondary and long-term (5 year) survival analysis of the ALLIANCE trial, n=66 VATS, n=686 open (propensity matched for analysis)	VATS versus open thoracotomy (pneumonectomy, lobectomy, bilobectomy, or segmentectomy) for NSCLC	Peri-operative			
				Median (range) operating time, minutes	<u>172 (40, 425)</u>	<u>118 (61, 450)</u>	<u><0.001</u>
				Post-operative			
				Median (range) LoS, days	<u>7 (0, 99)</u>	<u>4.5 (1, 19)</u>	<u><0.001</u>
				Operative mortality	1.6%	0	1.0
				Wound infection	0.4%	0	NR
				≥1 complication	47.8%	27.3%	0.44
				Post-discharge			
5 year overall survival (95% CI)	65.9 (62.3, 69.7)	71.6 (61.2, 83.6)	0.36				
Disease-free survival (95% CI)	69.2 (65.4, 73.3)	76.2 (63.5, 89.1)	0.55				
Local disease-free survival (95% CI)	92.6 (90.2, 95.0)	88.0 (78.6, 98.5)	0.26				
Paul et al. 2013²⁸	United States	Retrospective database analysis (Nationwide Inpatient Sample), n=10,554 thoracoscopy; n=57,796 thoracotomy, propensity matched	Thoracoscopy versus thoracotomy for lobectomy (2007–2008)	Peri-operative			
				Puncture/laceration	1.1%	0.9%	0.422
				Bleeding	1.5%	1.7%	0.474
				Post-operative			
				Mortality	<u>2.3%</u>	<u>1.6%</u>	<u>0.0062</u>
				Median (range) LoS, days	<u>7 (5, 9)</u>	<u>5 (3, 8)</u>	<u><0.001</u>
				Any complication	<u>50.4%</u>	<u>46.5%</u>	<u>0.003</u>
Pneumonia	8.2%	7.3%	0.170				
Wound infection	0.6%	0.3%	0.053				
Kent et al. 2014²⁹	United States	Retrospective national database analysis, n=20,238 open; n=12,427 VATS, n=430 robotic (not presented), propensity matched	Open versus VATS versus robotic lobectomy or segmentectomy (2008–2010)	Post-operative			
				Mortality	2.0%	1.1%	NR
				Mean LoS, days	8.2	6.3	NR
				Routine discharge	59.5%	64.5%	NR
				Prolonged LoS	9.6%	6.9%	NR
				Any complication	54.1%	45.3%	NR
				Bleeding complication	1.9%	1.3%	NR
Farjah et al. 2014³⁰	United States	Retrospective study using the MarketScan database, n=6,893	VATS versus open lobectomy for lung cancer (2007–2011)	Post-operative			
				Median LoS, days	<u>6</u>	<u>4</u>	<u><0.001</u>
				Prolonged LoS	<u>7.2%</u>	<u>3.0%</u>	<u><0.001</u>
				90-day re-admission	<u>12%</u>	<u>10%</u>	<u>0.026</u>

Table 1-2 Summary of key clinical studies comparing video-assisted versus open thoracic surgery							
Study	Setting	Study details	Procedure (year performed)	Summary of clinical findings Endpoint	Open	VATS	P value
		thoracotomy, n=3,069					
Gopaldas et al. 2010³¹	United States	Retrospective national database analysis; n=12,860 thoracotomy; n=759 VATS	VATS versus open lobectomy (2004–2006)	Post-operative LoS, days Mortality Total complications Wound Infection Cardiovascular <u>Intraoperative</u> Systemic Gastrointestinal Urinary Pulmonary	9.3 (0.1) 3.1% 43.1% 0.8% 0.6% 3.4% <u>2.8%</u> 1.0% 1.2% 1.1% 32.2%	9.2 (0.4) 3.4% 44.1% 1.3% 0.5% 3.9% <u>4.1%</u> 1.2% 1.1% 0.8% 31.2%	0.696 0.676 0.592 1.151 0.726 0.431 <u>0.033</u> 0.563 0.792 0.398 0.548
Paul et al. 2014³²	United States	Retrospective national database analysis, n=5,042 thoracotomy, n=1,281 thoracoscopy, (propensity matched)	Thoracotomy versus thoracoscopy for lobectomy (2002–2007)	Post-operative <u>Any complication</u> 30-day/discharge mortality <u>Pulmonary complication</u> Pneumonia <u>Cardiovascular complication</u> Bleeding requiring reoperation <u>Blood transfusion</u> <u>Any infection</u>	<u>34.7%</u> 1.01% <u>12.2%</u> 4.4% <u>13.0%</u> 0.6% <u>4.7%</u> <u>3.8%</u>	<u>26.2%</u> 0.94% <u>7.6%</u> 3.0% <u>8.3%</u> 1.3% <u>2.4%</u> <u>2.0%</u>	<u><0.0001</u> 1.00 <u>0.0001</u> 0.0758 <u>0.0002</u> 0.0931 <u>0.0028</u> <u>0.0141</u>
Park et al. 2012³³	United States	Retrospective database analysis, n=4,769 open, n=1,523 VATS	VATS versus open surgery for lobectomy for lung cancer (2008)	Post-operative <u>Total complications</u> <u>Median LoS, days</u> Mortality	<u>43.5%</u> <u>7</u> 2.2%	<u>38.3%</u> <u>5</u> 1.5%	<u><0.001</u> <u><0.001</u> 0.12
Paul et al. 2014³⁴	United States	Retrospective national database, n=4,715 open, n=1,293 thoracoscopy, propensity matched	Thoracotomy versus thoracoscopic lobectomy for lung cancer (2007–2009)	Post-operative <u>Mean (SD) LoS, days</u> <u>Median (IQR) LoS, days</u> <u>In-hospital mortality</u>	<u>8.7 (6.6)</u> <u>7 (5, 10)</u> <u>43 (3.6)</u>	<u>6.6 (6)</u> <u>5 (3, 8)</u> <u>25 (2.1)</u>	<u><0.0001</u> <u><0.001</u> <u>0.0290</u>

Table 1-2 Summary of key clinical studies comparing video-assisted versus open thoracic surgery							
Study	Setting	Study details	Procedure (year performed)	Summary of clinical findings Endpoint	Open	VATS	P value
Falcoz et al. 2015³⁵	Multinational (Europe)	Retrospective analysis of the ESTS database, n=2,721 open; n=2,721 VATS propensity matched patients	VATS versus open lobectomy for lung cancer (2007–2013)	Post-operative			
				Mean (SD) LoS	9.8 (6.9)	7.8 (5.8)	NR
				<u>Any complication</u>	<u>31.7%</u>	<u>29.1%</u>	<u>0.0357</u>
				<u>Major cardiopulmonary complication</u>	<u>19.6%</u>	<u>15.9%</u>	<u>0.0094</u>
				Air leak duration <5 days	9.2%	10.1%	0.2363
				Pneumonia	6.2%	6.0%	0.7739
				Reoperation for bleeding	1.5%	1.5%	1
				<u>Wound infection</u>	<u>0.6%</u>	<u>0.2%</u>	<u>0.0218</u>
<u>Death</u>	<u>1.9%</u>	<u>1.0%</u>	<u>0.0201</u>				
Swanson et al. 2012³⁶	United States	Retrospective database analysis, n=2,907 open, n=1,054 VATS	Open versus VATS lobectomy (2007–2008)	Peri-operative			
				Mean (SD) operation time, hours	<u>3.75 (0.47)</u>	<u>4.09 (0.52)</u>	<u>0.000</u>
				Post-operative			
Mean (SD) LoS, days	<u>7.83 (2.05)</u>	<u>6.15 (1.61)</u>	<u>0.000</u>				
Howington et al. 2012³⁷	United States	Retrospective database analysis; n=999 open; n=1,052 VATS	VATS versus open wedge resection in lung cancer (2007–2008)	Peri-operative			
				Mean (SD) operating time, hours	<u>3:16 (0:43)</u>	<u>2:82 (0:38)</u>	<u>0.000</u>
				Mean (SD) LoS, days	<u>6.34 (2.31)</u>	<u>4.44 (1.62)</u>	<u>0.000</u>
Laursen et al. 2015³⁸	Denmark	Retrospective database analysis of prospectively collected data, n=785 VATS and 594 thoracotomy	VATS versus open (thoracotomy) lobectomy for lung cancer (2005–2011)	Peri-operative			
				Median blood loss, mL	<u>300</u>	<u>100</u>	<u><0.001</u>
				Median operating time, minutes	<u>155</u>	<u>125</u>	<u><0.001</u>
				Median pleural cavity drainage, days	<u>4.0</u>	<u>3.0</u>	<u><0.001</u>
				Post-operative			
				Median (range) LoS, days	<u>7.00 (2–61)</u>	<u>5.00 (1–65)</u>	<u><0.001</u>
				Conversion	NA	4.5%	NA
				Re-do operation	5.2%	4.2%	0.375
				<u>Minor complication</u>	<u>48.5%</u>	<u>36.3%</u>	<u><0.001</u>
				<u>Major complication</u>	<u>35.7%</u>	<u>20.0%</u>	<u><0.001</u>
<u>Pneumonia</u>	<u>10.6%</u>	<u>7.5%</u>	<u>0.045</u>				
<u>Transfusion</u>	<u>23.2%</u>	<u>7.0%</u>	<u><0.001</u>				
<u>ICU</u>	<u>4.0%</u>	<u>1.5%</u>	<u>0.004</u>				
<u>Infection without specification</u>	<u>8.4%</u>	<u>2.7%</u>	<u><0.001</u>				

Table 1-2 Summary of key clinical studies comparing video-assisted versus open thoracic surgery							
Study	Setting	Study details	Procedure (year performed)	Summary of clinical findings Endpoint	Open	VATS	P value
Villamizar et al. 2009 ³⁹	United States	Retrospective database of prospectively collected data, n=697 thoracoscopic, n=382 thoracotomy, propensity matched analysis	Thoracoscopy versus thoracotomy for lobectomy (1999–2009)	Post-operative			
				Median (IQR) LoS, days	<u>5 (4, 7)</u>	<u>4 (3, 6)</u>	<u>0.0001</u>
				Median (IQR) chest tube duration, days	<u>4 (3, 6)</u>	<u>3 (2, 4)</u>	<u>0.0001</u>
				Mortality	5%	3%	0.20
				No complications	<u>51%</u>	<u>69%</u>	<u>0.0001</u>
				Transfusion	<u>13%</u>	<u>4%</u>	<u>0.002</u>
				Wound infection	1%	0.4%	0.62
				Pneumonia	<u>10%</u>	<u>5%</u>	<u>0.05</u>
Yang et al. 2009 ⁴⁰	China	Retrospective analysis, n=120 VATS, n=501 open	VATS versus open lobectomy for lung cancer (1996–2003)	Peri-operative			
				Conversions	—	5.8%	NA
				Median operating time, minutes	125	152	NR
				Post-operative			
				Median LoS	9	8.6	NR
				Median blood loss, mL	250	130	NR
				Median drainage time, days	3.5	3.5	NR
				30 day mortality	0.9%	0%	NR
				Post-operative complications	11.2%	10.6%	NR
				Pneumonia	3.1%	3.5%	NR
				Post-discharge			
				5 year survival			
Stage I NSCLC	81.6%	79.1%	NR				
Stage II NSCLC	47.2%	45.5%	NR				
Stage III+ NSCLC	24.1%	22.2%	NR				
Flores et al. 2009 ⁴¹	United States	Retrospective database analysis of prospectively collected data n=398 VATS lobectomy, n=343 thoracotomy, propensity matched	VATS versus thoracotomy for lobectomy in stage 1A non-small cell lung cancer (2002–2007)	Peri-operative			
				Median operating time, hours	3:44	3:40	NR
				Conversions	—	17%	NA
				Post-operative			
				Complications (any)	30%	24%	0.05
				LoS, days	<u>7</u>	<u>5</u>	<u><0.0001</u>
5-year survival	75%	79%	0.08				
Chen et al. 2014 ⁴²	China	Retrospective chart review, n=310	VATS versus thoracotomy for pulmonary	Peri-operative			
				Median operating time, minutes	151	138	0.063
				Blood loss, mL	128	118	0.06

Table 1-2 Summary of key clinical studies comparing video-assisted versus open thoracic surgery							
Study	Setting	Study details	Procedure (year performed)	Summary of clinical findings Endpoint	Open	VATS	P value
		thoracotomy, n=76 VATS	aspergilloma (lobectomy ± segmentectomy, bilobectomy, wedge resection, pneumonectomy) (2005–2012)	Post-operative <u>Median LoS, days</u> Post-operative pain	<u>14</u>	<u>10</u>	<u>0.016</u>
				Day 0	4.2	2.6	NR
				Day 1	5.35	3.03	NR
				Day 2	4.76	2.8	NR
				Day 3	4.25	2.7	NR
				Day 7	4.18	2.4	NR
				Day 14	4.0	0.95	NR
				Day 30	3.6	0.78	NR
Casali et al. 2009⁴³	United Kingdom	Retrospective single center analysis, n=93 VATS lobectomy, n=253 thoracotomy	Video-assisted thoracoscopic lobectomy versus open (thoracotomy) lobectomy for early stage lung cancer (2004–2006)	Peri-operative <u>Mean (SD) Time in theatre, minutes</u> Air leak Surgical emphysema Post-operative <u>Mean (SD) HDU length of stay, days</u> <u>Mean (SD) ward length of stay, days</u> <u>Mean (SD) post-operative hospital stay, days</u> Wound infection Pneumonia/chest infection	<u>140 (42)</u> 8.7% 0.4% <u>2.21 (0.07)</u> <u>4.66 (0.17)</u> <u>6.87 (0.19)</u> 2.0% 15.0%	<u>163 (34)</u> 12.9% 4.3% <u>1.48 (0.2)</u> <u>4.06 (0.3)</u> <u>5.54 (0.37)</u> 1.1% 11.8%	<u>0.00001</u> NR NR <u>0.0001</u> <u>0.0001</u> <u>0.001</u> NR NR
Ramos et al. 2012⁴⁴	France	Retrospective single center analysis, n=98 thoracoscopy, n=189 thoracotomy	Thoracoscopic versus open lobectomy for stage I non-small cell lung cancer (2007–2009)	Peri-operative <u>Median (IQR) operating time, minutes</u> Post-operative <u>Median LoS, days</u> Pneumonia Air leak Transfusion Reoperation	<u>142.0 (40.0)</u> <u>8.0</u> 9.5% 11.6% 4.2% 2.1%	<u>219.0 (56.5)</u> <u>7.0</u> 4.1% 6.1% 1.1% 1.0%	<u><0.001</u> <u><0.001</u> 0.100 0.139 0.174 0.665

Table 1-2 Summary of key clinical studies comparing video-assisted versus open thoracic surgery							
Study	Setting	Study details	Procedure (year performed)	Summary of clinical findings Endpoint	Open	VATS	P value
Ilonen et al. 2011 ⁴⁵	Finland	Retrospective observational study, n=116 VATS, n=116 thoracotomy, propensity matched	VATS versus open thoracotomy in stage I NSCLC lobectomy, bilobectomy or segmentectomy (2000–2010)	Post-operative			
				<u>Mean (SD) LoS, days</u>	<u>10.8 (7.4)</u>	<u>2.9 (1.7)</u>	<u>0.001</u>
				In hospital mortality	3.4%	2.6%	1
				<u>Complications</u>	<u>26.7%</u>	<u>15.5%</u>	<u>0.026</u>
Handy et al. 2010 ⁴⁶	United States	Retrospective analysis of prospectively collected data, n=49 VATS, n=192 open	VATS versus open lobectomy for non-small cell lung cancer (1998–2007)	Peri-operative			
				Operation time, minutes	144	152	0.29
				<u>Estimated blood loss, mL</u>	<u>470</u>	<u>204</u>	<u>0.00</u>
				<u>Blood transfusion</u>	<u>24%</u>	<u>4.2%</u>	<u>0.00</u>
				Post-operative			
				In hospital mortality	2.6%	4.1%	0.58
				<u>LoS, days</u>	<u>6.6</u>	<u>5.2</u>	<u>0.03</u>
				Post-op ventilation >48h	4.7%	2.0%	0.40
				Pneumonia	7.9%	4.1%	0.36
				Reintubation	9.4%	4.1%	0.22
				Wound infection	1.6%	2.0%	0.82
				Pulmonary embolism	1.0%	0.0%	0.47
				Chest tube >5 days	15%	14%	0.94
				Readmission to ICU	8.9%	6.1%	0.53
				Post-discharge (6 months)			
6-month mortality	8.3%	4.1%	0.31				
<u>Readmission to hospital</u>	<u>20%</u>	<u>3.6%</u>	<u>0.03</u>				
FEV ₁ decrease, L ²	-0.27	-0.49	0.17				
Chronic pain	29%	21%	0.43				
<u>Requiring pain medicine</u>	<u>36%</u>	<u>7.1%</u>	<u>0.00</u>				
Pan et al. 2012 ⁴⁷	China	Retrospective single center study, n=83 VATS, n=97 thoracotomy	VATS versus thoracotomy for lobectomy for non-small cell lung	Peri-operative			
				Mean (SD) blood loss, mL	245 (79)	178 (56)	0.098
				<u>Mean (SD) operating time, minutes</u>	<u>124 (81)</u>	<u>176 (68)</u>	<u>0.046</u>

² FEV₁, forced expiratory volume in one second; a lower post-operative decrease shows less change in pulmonary function following surgery

Table 1-2 Study	Setting	Study details	Procedure (year performed)	Summary of clinical findings Endpoint	Open	VATS	P value
			cancer (2008–2010)	Post-operative Mean (SD) pleural cavity drainage; days Mean (SD) LoS, days	4.8 (2.7) <u>9.5 (2.3)</u>	3.6 (1.2) <u>7.5 (1.9)</u>	0.395 <u>0.043</u>
Deen et al. 2014 ⁴⁸	United States	Retrospective analysis, n=69 open, n=58 VATS and n=57 robotic (not presented in analysis)	Open versus VATS and robotic VATS (not presented) lobectomy or segmentectomy for stage I or II NSCLC, carcinoid or metastatic foci (2008–2012)	Peri-operative <u>Mean operating time, minutes</u> Post-operative Mean LoS, days Complication rate	<u>180</u> 5.47 30%	<u>202</u> 4.75 31%	<u>0.02</u> 0.11 0.942
Witte et al. 2015 ⁴⁹	Germany	Prospective non-randomized comparison of registry data, n=44 open, n=56 VATS	VATS versus open thoracotomy for pulmonary segmentectomy for lung carcinoma (2002–2012)	Peri-operative <u>Mean operative time, minutes</u> Post-operative Reintervention Duration of chest tube drainage, days (IQR) <u>LoS, days (IQR)</u> Post-discharge 5-year outcomes <u>Overall survival</u> Recurrence-free survival	<u>195.1 (57.3)</u> 22.7% 7 (5, 9) <u>12 (9, 16)</u> 69.9% 48.6%	<u>224.8 (61.6)</u> 23.2% 7 (4, 10) <u>9 (7.75, 14)</u> 86% 58.5%	<u>0.014</u> 1.00 0.807 <u>0.034</u> <u>0.047</u> 0.480
Bu et al. 2012 ⁵⁰	China	Retrospective single center study, n=46 VATS and n=87 thoracotomy included in study	VATS versus thoracotomy for lobectomy for non-small cell lung cancer with tumors >5 cm (2001–2011)	Peri-operative <u>Mean (SD) operating time, minutes</u> <u>Mean (SD) blood loss, mL</u> Post-operative Complications Mean (SD) duration of drainage, days Mean (SD) LoS, days Post-discharge	<u>256.7 (67.5)</u> <u>556.9 (187.2)</u> 19.5% 7.5 (6.5) 12.7 (6.8)	<u>186.5 (62.8)</u> <u>218.5 (174.6)</u> 8.7% 8.0 (3.5) 11.3 (5.9)	<0.001 <0.001 0.103 0.508 0.241

Table 1-2 Summary of key clinical studies comparing video-assisted versus open thoracic surgery							
Study	Setting	Study details	Procedure (year performed)	Summary of clinical findings Endpoint	Open	VATS	P value
				Recurrence	3.8%	2.4%	0.670
				3-year survival	64.0%	69.6%	NR
Li et al. 2012⁵¹	China	Retrospective analysis, n=47 thoracotomy, n=29 VATS	Thoracotomy versus VATS lobectomy for NSCLC (2000–2009)	Peri-operative <u>Operating time, minutes</u> <u>Blood loss, mL</u> Post-operative Chest drain, days LoS, days	<u>235</u> <u>400</u> 7.5 (6.6–8.7) 11.0 (10.6–12.8)	<u>195</u> <u>200</u> 8.0 (6.7–10.3) 11.0 (9.8–14.5)	<u>0.003</u> <u>0.002</u> 0.308 0.498
Leshnower et al. 2010⁵²	United States	Retrospective single center analysis, n=26 thoracotomy (open); n=15 VATS (thoracoscopic)	Video-assisted versus open segmentectomy (2002–2009)	Peri-operative Mean (SD) operating room time, minutes Post-operative <u>Mean (SD) chest tube duration, days</u> <u>Mean (SD) LoS, days</u> Mortality Discharge to home	140 (38) 5.2 (3.0) 8.3 (6.1) 8% 85%	145 (55) 2.8 (1.3) 3.5 (1.4) 0% 100%	0.70 0.001 0.01 0.27 0.63

ESTS, European Society of Thoracic Surgeons; FEV1, forced expiratory volume in 1 second; IQR, inter-quartile range; LoS, length of stay; VATS, video-assisted thoracic surgery

Table 1-3 Summary of key studies comparing economic outcomes of video assisted versus open thoracic surgery								
Study	Setting	Study details	Procedures	Currency (Cost year)	Cost Outcome	Open	VATS	P value
Casali et al. 2009 ⁴³	United Kingdom	Retrospective single center analysis, n=93 VATS lobectomy, n=253 thoracotomy	Video-assisted thoracoscopic lobectomy versus open (thoracotomy) lobectomy for early stage lung cancer (2004–2006)	EUR (year not stated)	<u>Theater cost</u>	<u>1,280 (54)</u>	<u>2,533 (230)</u>	<u>0.00001</u>
					<u>HDU stay cost</u>	<u>2,571 (80)</u>	<u>1,713 (236)</u>	<u>0.00001</u>
					<u>Ward stay cost</u>	<u>4,325 (154)</u>	<u>3,776 (281)</u>	<u>0.00001</u>
					<u>Total cost</u>	<u>8,178 (167)</u>	<u>8,023 (565)</u>	<u>0.00002</u>
Leshnowar et al. 2010 ⁵²	United States	Retrospective single center analysis, n=26 open; n=15 VATS	Video-assisted versus open segmentectomy (2002–2009)	USD (year not stated)	Total cost	46,798	45,101	0.56
Cho et al. 2011 ⁵³	Korea	Prospective single center study, n=86 VATS, n=97 open	Video-assisted thoracic surgery (VATS) versus open lobectomy for non-small cell lung cancer (2007–2009)	USD (year not stated)	All patients			
					Total hospital cost	5,593	5,391	0.098
					<u>Ward stay cost</u>	<u>429</u>	<u>268</u>	<u>0.000</u>
					Anesthesia cost	474	435	0.193
					<u>Surgical material cost</u>	<u>1,365</u>	<u>1,742</u>	<u>0.000</u>
					Surgical fee	911	910	0.884
					Benefit-service cost	4,119	3,882	0.139
					Non-benefit-service cost	1,144	1,305	0.674
					Patients without complications			
					Total hospital cost	4,769	4,684	0.891
<u>Ward stay cost</u>	<u>327</u>	<u>234</u>	<u>0.000</u>					
Anesthesia cost	478	455	0.322					
<u>Surgical material cost</u>	<u>1,306</u>	<u>1,853</u>	<u>0.000</u>					
Gopaldas et al. 2010 ⁵¹	United States	Retrospective national database; n=12,860 open; n=759 VATS	VATS versus open lobectomy (2004–2006)	USD (year not stated)	Hospitalization cost	23,862 (206)	25,125 (1,093)	NR

Table 1-3 Summary of key studies comparing economic outcomes of video assisted versus open thoracic surgery								
Study	Setting	Study details	Procedures	Currency (Cost year)	Cost Outcome	Open	VATS	P value
Divisi et al. 2015⁵⁴	Italy	Retrospective single center study, n=61 VATS, n=61 pleural drainage	VATS versus pleural drainage for primary spontaneous pneumothorax (2006–2012)	EUR (year not stated)	Total cost ICER, VATS versus pleural drainage, EUR per QALY gained at 1 year 2 years 3 years 4 years 5 years	Chest tube 4209 7,600 7,908 8,237 9,227 10,045	VATS 2319	NR
Fang et al. 2014⁵⁵	Taiwan	Retrospective database analysis, n=966 propensity matched	VATS versus open surgery for stage I NSCLC (lobectomy or sublobectomy, wedge or segmental resection) (2007–2009)	USD (2013)	Cost Life years ICER, USD per life year gained for VATS compared with open surgery	21,976 0.974 56,667	22,316 0.980	NR
Farjah et al. 2014³⁰	United States	Retrospective cohort study using the MarketScan database, n=6,893 thoracotomy, n=3,069 VATS	VATS versus open lobectomy for lung cancer (2007–2011)	USD (year not stated)	<u>Mean total 90 day costs</u> <u>Mean Index</u> <u>hospitalization costs</u> Mean 90-day readmission costs <u>Mean 90-day outpatient health care use costs</u> Mean 90-day outpatient pharmacy costs	<u>46,470</u> <u>37,673</u> 36,845 <u>3,828</u> 713	<u>42,076</u> <u>35,307</u> 35,550 <u>3,530</u> 672	<u>0.001</u> <u>0.002</u> 0.772 <u>0.043</u> 0.170
Howington et al. 2012³⁷	United States	Retrospective database analysis; n=999 open; n=1,052 VATS	VATS versus open wedge resection in lung cancer (2007–2008)	USD (year not stated)	<u>Hospital costs</u>	<u>17,377 (5,185)</u>	<u>14,795 (4,414)</u>	<u>0.000</u>

Table 1-3 Summary of key studies comparing economic outcomes of video assisted versus open thoracic surgery								
Study	Setting	Study details	Procedures	Currency (Cost year)	Cost Outcome	Open	VATS	P value
Ramos et al. 2012⁴⁴	France	Retrospective single center analysis, n=98 thoracoscopy, n=189 thoracotomy	Thoracoscopic versus open lobectomy for stage I non-small cell lung cancer (2007-2009)	EUR (year not stated)	<u>Mean hospital (ward) stay (SD)</u>	<u>3,171 (1,566)</u>	<u>2,503 (873)</u>	<u><0.001</u>
					HDU and ICU	2,612 (3,495)	1,929 (3,322)	0.167
					<u>Theatre + disposables</u>	<u>2,260 (399)</u>	<u>2,861 (458)</u>	<u><0.001</u>
					<u>Laboratory</u>	<u>662 (440)</u>	<u>479 (336)</u>	<u><0.001</u>
					<u>Radiology</u>	<u>578 (454)</u>	<u>452 (429)</u>	<u>0.014</u>
					<u>Total cost</u>	<u>14,146 (7,118)</u>	<u>11,934 (6,690)</u>	<u><0.001</u>
Chen et al. 2014⁴²	China	Retrospective chart review, n=310 thoracotomy, n=76 VATS	VATS versus thoracotomy for pulmonary aspergilloma (lobectomy ± segmentectomy, bilobectomy, wedge resection, pneumonectomy) (2005-2012)	CNY (year not stated)	<u>Total cost</u>	<u>49,000 (15,000)</u>	<u>43,000 (6,000)</u>	<u>0.016</u>
Park et al. 2012³³	United States	Retrospective database analysis, n=4,769 open, n=1,523 VATS	VATS versus open surgery for pulmonary lobectomy for lung cancer (2008)	USD (year not stated)	Median total cost	20,348	19,656	0.16
Swanson et al. 2012³⁶	United States	Retrospective database analysis, n=2,907 open, n=1,054 VATS	Open versus VATS lobectomy (2007-2008)	USD (year not stated)	<u>Adjusted hospital costs (SD)</u>	<u>21,016 (5,645)</u>	<u>20,316 (5,457)</u>	<u>0.027</u>
Deen et al. 2014⁴⁸	United States	Retrospective analysis, n=69 open, n=58 VATS and n=57 robotic (not presented in analysis)	Open versus VATS and robotic VATS (not presented) lobectomy or segmentectomy for stage I or II	USD (year not stated)	Procedure cost	15,036	13,663	0.169
					Operating room	4,301	4,520	0.248
					Ward	2,611	2,875	0.908
					<u>Supplies</u>	<u>2,097</u>	<u>2,683</u>	<u><0.001</u>
					<u>Staplers</u>	<u>1,537</u>	<u>2,033</u>	<u><0.001</u>
					<u>ICU</u>	<u>2,541</u>	<u>1,012</u>	<u>0.002</u>
<u>Respiratory therapy</u>	<u>1,084</u>	<u>730</u>	<u>0.025</u>					

Table 1-3 Summary of key studies comparing economic outcomes of video assisted versus open thoracic surgery								
Study	Setting	Study details	Procedures	Currency (Cost year)	Cost Outcome	Open	VATS	P value
			NSCLC, carcinoid or metastatic foci (2008–2012)		<u>Laboratory</u>	<u>936</u>	<u>564</u>	<u><0.001</u>
					Pharmacy	590	549	0.603
					Imaging	568	530	0.494
Burfeind et al. 2010 ⁵⁶	United States	Cost minimization analysis	Thoracoscopy versus posterolateral thoracotomy for lobectomy	USD (year not stated)	Preoperative cost	722 (963)	419 (441)	NR
					Hospitalization	8,251 (2,958)	7,144 (2,148)	NR
					Post-operative	464 (1,313)	398 (1,402)	NR
					Professional	2,694 (1,473)	2,122 (1,467)	NR
					<u>Total costs</u>	<u>12,119 (3,476)</u>	<u>10,084 (2,820)</u>	<u>0.0012</u>
Li et al. 2012 ⁵¹	China	Retrospective analysis, n=47 thoracotomy, n=29 VATS	Thoracotomy versus VATS lobectomy for NSCLC (2000–2009)	CNY (year not stated)	<u>Total cost</u>	<u>30,300 (28,600, 36,300)</u>	<u>48,500 (41,200, 56,700)</u>	<u>0.000</u>

HDU, high dependency unit; ICER; incremental cost-effectiveness ratio; ICU, intensive care unit; NSCLC, non-small cell lung cancer; QALY, quality-adjusted life year; SD, standard deviation; VATS, video-assisted thoracic surgery

1.3. References

- ¹ Mohiuddin K, Swanson SJ. Maximizing the benefit of minimally invasive surgery. *J Surg Oncol*. 2013 Oct;108(5):315-9 (PMID: [24037974](#))
- ² Cancer.org What are the key statistics about lung cancer? Available at: <http://www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/non-small-cell-lung-cancer-key-statistics> [Last accessed August 26, 2015]
- ³ European Respiratory Society White Book lung cancer. Available at: <http://www.erswhitebook.org/chapters/lung-cancer/> [Last accessed August 26, 2015]
- ⁴ Wakeam E, Hyder JA, Lipsitz SR, Darling GE, Finlayson SR. Outcomes and Costs for Major Lung Resection in the United States: Which Patients Benefit Most From High-Volume Referral? *Ann Thorac Surg*. 2015 Sep;100(3):939-46 (PMID: [26116480](#))
- ⁵ Pischik VG. Technical difficulties and extending the indications for VATS lobectomy. *J Thorac Dis*. 2014 Oct;6(Suppl 6):S623-30 (PMID: [25379200](#))
- ⁶ Solaini L, Prusciano F, Bagioni P, di Francesco F, Solaini L, Poddie DB. Video-assisted thoracic surgery (VATS) of the lung: analysis of intraoperative and postoperative complications over 15 years and review of the literature. *Surg Endosc*. 2008 Feb;22(2):298-310 (PMID: [17943372](#))
- ⁷ Nwogu CE, Glinianski M, Demmy TL. Minimally invasive pneumonectomy. *Ann Thorac Surg*. 2006 Jul;82(1):e3-4 (PMID: [16798175](#))
- ⁸ Predina JD, Kunkala M, Aliperti LA, Singhal AK, Singhal S. Sleeve lobectomy: current indications and future directions. *Ann Thorac Cardiovasc Surg*. 2010 Oct;16(5):310-8 (PMID: [21030916](#))
- ⁹ Gonzalez-Rivas D, Fieira E, Delgado M, de la Torre M, Mendez L, Fernandez R. Uniportal video-assisted thoracoscopic sleeve lobectomy and other complex resections. *J Thorac Dis*. 2014 Oct;6(Suppl 6):S674-81 (PMID: [25379210](#))
- ¹⁰ Downey RJ, Cheng D, Kernstine K, Stanbridge R, Shennib H, Wolf R, Ohtsuka T, Schmid R, Waller D, Fernando H, Yim A, Martin J. Video-Assisted Thoracic Surgery for Lung Cancer Resection: A Consensus Statement of the International Society of Minimally Invasive Cardiothoracic Surgery (ISMICS) 2007. *Innovations (Phila)*. 2007 Nov;2(6):293-302 (PMID: [22437197](#))
- ¹¹ Goto T, Kadota Y, Mori T, Yamashita S, Horio H, Nagayasu T, Iwasaki A. Video-assisted thoracic surgery for pneumothorax: republication of a systematic review and a proposal by the guideline committee of the Japanese association for chest surgery 2014. *Gen Thorac Cardiovasc Surg*. 2015 Jan;63(1):8-13 (PMID: [25182971](#))
- ¹² Yamashita S, Goto T, Mori T, Horio H, Kadota Y, Nagayasu T, Iwasaki A. Video-assisted thoracic surgery for lung cancer: republication of a systematic review and a proposal by the guidelines committee of the Japanese Association for Chest Surgery 2014. *Gen Thorac Cardiovasc Surg*. 2014 Dec;62(12):701-5 (PMID: [25182970](#))
- ¹³ Howington JA, Blum MG, Chang AC, Balekian AA, Murthy SC. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*. 2013 May;143(5 Suppl):e278S-313S (PMID: [23649443](#))
- ¹⁴ Lee HS, Nam B-H, Zo J. Learning curves for video-assisted thoracic surgery lobectomy in non-small cell lung cancer. Abstract presented at the 89th meeting of the American

Association for Thoracic Surgery. 9-13 May 2009, Boston, MA, USA. Available at: <http://www.aats.org/annualmeeting/abstracts/2009/15.cgi> [Last accessed September 29, 2015]

¹⁵ David G, Gunnarsson CL, Moore M, Howington J, Miller DL, Maddaus MA, McKenna RJ Jr, Meyers BF, Swanson SJ. Surgeons' volume-outcome relationship for lobectomies and wedge resections for cancer using video-assisted thoracoscopic techniques. *Minim Invasive Surg*. 2012;2012:760292 (PMID: [23213500](#))

¹⁶ Zhao H, Bu L, Yang F, Li J, Li Y, Wang J. Video-assisted thoracoscopic surgery lobectomy for lung cancer: the learning curve. *World J Surg*. 2010 Oct;34(10):2368-72 (PMID: [20567972](#))

¹⁷ Cao C, Tian DH, Wolak K, Oparka J, He J, Dunning J, Walker WS, Yan TD. Cross-sectional survey on lobectomy approach (X-SOLA). *Chest*. 2014 Aug;146(2):292-8 (PMID: [24504007](#))

¹⁸ Medbery RL, Perez SD, Force SD, Gillespie TW, Pickens A, Miller DL, Fernandez FG. Video-assisted thoracic surgery lobectomy cost variability: implications for a bundled payment era. *Ann Thorac Surg*. 2014 May;97(5):1686-92 (PMID: [24792254](#))

¹⁹ Hu Y, McMurry TL, Isbell JM, Stukenborg GJ, Kozower BD. Readmission after lung cancer resection is associated with a 6-fold increase in 90-day postoperative mortality. *J Thorac Cardiovasc Surg*. 2014 Nov;148(5):2261-2267 (PMID: [24823283](#))

²⁰ Grogan EL, Jones DR. VATS lobectomy is better than open thoracotomy: what is the evidence for short-term outcomes? *Thorac Surg Clin*. 2008 Aug;18(3):249-58 (PMID: [18831499](#))

²¹ Kaseda S, Aoki T, Hangai N, Shimizu K. Better pulmonary function and prognosis with video-assisted thoracic surgery than with thoracotomy. *Ann Thorac Surg*. 2000 Nov;70(5):1644-6 (PMID: [11093502](#))

²² Sugiura H, Morikawa T, Kaji M, Sasamura Y, Kondo S, Katoh H. Long-term benefits for the quality of life after video-assisted thoracoscopic lobectomy in patients with lung cancer. *Surg Laparosc Endosc Percutan Tech*. 1999 Dec;9(6):403-8 (PMID: [10872623](#))

²³ Chen FF, Zhang D, Wang YL, Xiong B. Video-assisted thoracoscopic surgery lobectomy versus open lobectomy in patients with clinical stage I non-small cell lung cancer: a meta-analysis. *Eur J Surg Oncol*. 2013 Sep;39(9):957-63 (PMID: [23845704](#))

²⁴ Yan TD, Black D, Bannon PG, McCaughan BC. Systematic review and meta-analysis of randomized and nonrandomized trials on safety and efficacy of video-assisted thoracic surgery lobectomy for early-stage non-small-cell lung cancer. *J Clin Oncol*. 2009 May 20;27(15):2553-62 (PMID: [19289625](#))

²⁵ Cheng D, Downey RJ, Kernstine K, Stanbridge R, Shennib H, Wolf R, Ohtsuka T, Schmid R, Waller D, Fernando H, Yim A, Martin J. Video-assisted thoracic surgery in lung cancer resection: a meta-analysis and systematic review of controlled trials. *Innovations (Phila)*. 2007 Nov;2(6):261-92 (PMID: [22437196](#))

²⁶ Scott WJ, Allen MS, Darling G, Meyers B, Decker PA, Putnam JB, McKenna RW, Landrenau RJ, Jones DR, Inculet RI, Malthaner RA. Video-assisted thoracic surgery versus open lobectomy for lung cancer: a secondary analysis of data from the American College of Surgeons Oncology Group Z0030 randomized clinical trial. *J Thorac Cardiovasc Surg*. 2010 Apr;139(4):976-81 (PMID: [20172539](#))

-
- ²⁷ Su S, Scott WJ, Allen MS, Darling GE, Decker PA, McKenna RJ, Meyers BF. Patterns of survival and recurrence after surgical treatment of early stage non-small cell lung carcinoma in the ACOSOG Z0030 (ALLIANCE) trial. *J Thorac Cardiovasc Surg.* 2014 Feb;147(2):747-52 ([PMID: 24290575](#))
- ²⁸ Paul S, Sedrakyan A, Chiu YL, Nasar A, Port JL, Lee PC, Stiles BM, Altorki NK. Outcomes after lobectomy using thoracoscopy vs thoracotomy: a comparative effectiveness analysis utilizing the Nationwide Inpatient Sample database. *Eur J Cardiothorac Surg.* 2013 Apr;43(4):813-7 ([PMID: 22826474](#))
- ²⁹ Kent M, Wang T, Whyte R, Curran T, Flores R, Gangadharan S. Open, video-assisted thoracic surgery, and robotic lobectomy: review of a national database. *Ann Thorac Surg.* 2014 Jan;97(1):236-42 ([PMID: 24090577](#))
- ³⁰ Farjah F, Backhus LM, Varghese TK, Mulligan MS, Cheng AM, Alfonso-Cristancho R, Flum DR, Wood DE. Ninety-day costs of video-assisted thoracic surgery versus open lobectomy for lung cancer. *Ann Thorac Surg.* 2014 Jul;98(1):191-6 ([PMID: 24820393](#))
- ³¹ Gopaldas RR, Bakaeen FG, Dao TK, Walsh GL, Swisher SG, Chu D. Video-assisted thoracoscopic versus open thoracotomy lobectomy in a cohort of 13,619 patients. *Ann Thorac Surg.* 2010 May;89(5):1563-70 ([PMID: 20417778](#))
- ³² Paul S, Altorki NK, Sheng S, Lee PC, Harpole DH, Onaitis MW, Stiles BM, Port JL, D'Amico TA. Thoracoscopic lobectomy is associated with lower morbidity than open lobectomy: a propensity-matched analysis from the STS database. *J Thorac Cardiovasc Surg.* 2010 Feb;139(2):366-78 ([PMID: 20106398](#))
- ³³ Park HS, Detterbeck FC, Boffa DJ, Kim AW. Impact of hospital volume of thoracoscopic lobectomy on primary lung cancer outcomes. *Ann Thorac Surg.* 2012 Feb;93(2):372-9 ([PMID: 21945225](#))
- ³⁴ Paul S, Isaacs AJ, Treasure T, Altorki NK, Sedrakyan A. Long term survival with thoracoscopic versus open lobectomy: propensity matched comparative analysis using SEER-Medicare database. *BMJ.* 2014 Oct 2;349:g5575 ([PMID: 25277994](#))
- ³⁵ Falcoz PE, Puyraveau M, Thomas PA, Decaluwe H, Hürtgen M, Petersen RH, Hansen H, Brunelli A; ESTS Database Committee and ESTS Minimally Invasive Interest Group. Video-assisted thoracoscopic surgery versus open lobectomy for primary non-small-cell lung cancer: a propensity-matched analysis of outcome from the European Society of Thoracic Surgeon database. *Eur J Cardiothorac Surg.* 2015 Apr 26. pii: ezv154. [Epub ahead of print] ([PMID: 25913824](#))
- ³⁶ Swanson SJ, Meyers BF, Gunnarsson CL, Moore M, Howington JA, Maddaus MA, McKenna RJ, Miller DL. Video-assisted thoracoscopic lobectomy is less costly and morbid than open lobectomy: a retrospective multiinstitutional database analysis. *Ann Thorac Surg.* 2012 Apr;93(4):1027-32 ([PMID: 22130269](#))
- ³⁷ Howington JA, Gunnarsson CL, Maddaus MA, McKenna RJ, Meyers BF, Miller D, Moore M, Rizzo JA, Swanson S. In-hospital clinical and economic consequences of pulmonary wedge resections for cancer using video-assisted thoracoscopic techniques vs traditional open resections: a retrospective database analysis. *Chest.* 2012 Feb;141(2):429-35 ([PMID: 21778260](#))
- ³⁸ Laursen LØ, Petersen RH, Hansen HJ, Jensen TK, Ravn J, Konge L. Video-assisted thoracoscopic surgery lobectomy for lung cancer is associated with a lower 30-day morbidity compared with lobectomy by thoracotomy. *Eur J Cardiothorac Surg.* 2015 Jun 18. pii: ezv205. [Epub ahead of print] ([PMID: 26088592](#))

-
- ³⁹ Villamizar NR, Darrabie MD, Burfeind WR, Petersen RP, Onaitis MW, Toloza E, Harpole DH, D'Amico TA. Thoracoscopic lobectomy is associated with lower morbidity compared with thoracotomy. *J Thorac Cardiovasc Surg*. 2009 Aug;138(2):419-25 ([PMID: 19619789](#))
- ⁴⁰ Yang X, Wang S, Qu J. Video-assisted thoracic surgery (VATS) compares favorably with thoracotomy for the treatment of lung cancer: a five-year outcome comparison. *World J Surg*. 2009 Sep;33(9):1857-61 ([PMID: 19626361](#))
- ⁴¹ Flores RM, Park BJ, Dycoco J, Aronova A, Hirth Y, Rizk NP, Bains M, Downey RJ, Rusch VW. Lobectomy by video-assisted thoracic surgery (VATS) versus thoracotomy for lung cancer. *J Thorac Cardiovasc Surg*. 2009 Jul;138(1):11-8 ([PMID: 19577048](#))
- ⁴² Chen QK, Chen C, Chen XF, Jiang GN. Video-assisted thoracic surgery for pulmonary aspergilloma: a safe and effective procedure. *Ann Thorac Surg*. 2014 Jan;97(1):218-23 ([PMID: 24094518](#))
- ⁴³ Casali G, Walker WS. Video-assisted thoracic surgery lobectomy: can we afford it? *Eur J Cardiothorac Surg*. 2009 Mar;35(3):423-8 ([PMID: 19136272](#))
- ⁴⁴ Ramos R, Masuet C, Gossot D. Lobectomy for early-stage lung carcinoma: a cost analysis of full thoracoscopy versus posterolateral thoracotomy. *Surg Endosc*. 2012 Feb;26(2):431-7 ([PMID: 21898011](#))
- ⁴⁵ Ilonen IK, Räsänen JV, Knuutila A, Salo JA, Sihvo EI. Anatomic thoracoscopic lung resection for non-small cell lung cancer in stage I is associated with less morbidity and shorter hospitalization than thoracotomy. *Acta Oncol*. 2011 Oct;50(7):1126-32 ([PMID: 21314296](#))
- ⁴⁶ Handy JR Jr, Asaph JW, Douville EC, Ott GY, Grunkemeier GL, Wu Y. Does video-assisted thoracoscopic lobectomy for lung cancer provide improved functional outcomes compared with open lobectomy? *Eur J Cardiothorac Surg*. 2010 Feb;37(2):451-5 ([PMID: 19747837](#))
- ⁴⁷ Pan TW, Wu B, Xu ZF, Zhao XW, Zhong L. Video-assisted thoracic surgery versus thoracotomy for non-small-cell lung cancer. *Asian Pac J Cancer Prev*. 2012;13(2):447-50 ([PMID: 22524804](#))
- ⁴⁸ Deen SA, Wilson JL, Wilshire CL, Vallières E, Farivar AS, Aye RW, Ely RE, Louie BE. Defining the cost of care for lobectomy and segmentectomy: a comparison of open, video-assisted thoracoscopic, and robotic approaches. *Ann Thorac Surg*. 2014 Mar;97(3):1000-7 ([PMID: 24480259](#))
- ⁴⁹ Witte B, Stenz C, Vahl CF, Huertgen M. Comparative intention-to-treat analysis of the video-assisted thoracoscopic surgery approach to pulmonary segmentectomy for lung carcinoma. *Interact Cardiovasc Thorac Surg*. 2015 Jun 10. pii: ivv143. [Epub ahead of print] ([PMID: 26063694](#))
- ⁵⁰ Bu L, Li Y, Yang F, Zhao H, Jiang GC, Li JF, Liu J, Wang J. Completely video-assisted thoracoscopic lobectomy versus open lobectomy for non-small cell lung cancer greater than 5 cm: a retrospective study. *Chin Med J (Engl)*. 2012 Feb;125(3):434-9 ([PMID: 22490398](#))
- ⁵¹ Li Y, Wang J. Comparison of clinical outcomes for patients with clinical N0 and pathologic N2 non-small cell lung cancer after thoracoscopic lobectomy and open lobectomy: a retrospective analysis of 76 patients. *J Surg Oncol*. 2012 Sep 15;106(4):431-5 ([PMID: 22442010](#))
- ⁵² Leshnower BG, Miller DL, Fernandez FG, Pickens A, Force SD. Video-assisted thoracoscopic surgery segmentectomy: a safe and effective procedure. *Ann Thorac Surg*. 2010 May;89(5):1571-6 ([PMID: 20417779](#))

⁵³ Cho S, Do YW, Lee EB. Comparison of costs for video-assisted thoracic surgery lobectomy and open lobectomy for non-small cell lung cancer. *Surg Endosc.* 2011 Apr;25(4):1054-61 ([PMID: 20835729](#))

⁵⁴ Divisi D, Di Leonardo G, Crisci R. Video-assisted thoracic surgery versus pleural drainage in the management of the first episode of primary spontaneous pneumothorax. *Am J Surg.* 2015 Jul;210(1):68-73 ([PMID: 25769881](#))

⁵⁵ Fang HY, Hsiao FY, Huang HC, Lin YS, Chen CY, Shieh SH, Chen PR, Chen CK, Chien CR. Cost and effectiveness of video-assisted thoracoscopic surgery for clinical stage I non-small cell lung cancer: a population-based analysis. *J Thorac Dis.* 2014 Dec;6(12):1690-6 ([PMID: 25589961](#))

⁵⁶ Burfeind WR Jr, Jaik NP, Villamizar N, Toloza EM, Harpole DH Jr, D'Amico TA. A cost-minimisation analysis of lobectomy: thoracoscopic versus posterolateral thoracotomy. *Eur J Cardiothorac Surg.* 2010 Apr;37(4):827-32 ([PMID: 19939695](#))

© 2016 Medtronic. All rights reserved. Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic. All other brands are trademarks of a Medtronic company. 04/2016 US160336